Partial digestion
Gluten fragments remain immunologically relevant after digestion and reach the mucosal environment.
Next-generation coeliac disease research
TransGlutex is a fictional gut-targeted TG2 modulator in a delayed extended-release OROS tablet.
Glutopia Pharmaceuticals is developing TransGlutex, a fictional 100 mg oral small-molecule concept designed to engage the GTP-binding pocket of tissue transglutaminase 2 while using an enteric-coated OROS osmotic pump to support gut-restricted delivery.
TransGlutexLead product concept
100 mgPer tablet
OROSEnteric-coated delivery
Allosteric TG2
OROS osmotic pump
SwissADME-guided optimization
Investor-ready narrative
Mission statement
We design precise, gut-focused therapies that may help protect coeliac patients from accidental gluten exposure.
Our mission is to develop innovative, locally acting small molecules that reduce the immunogenicity of gluten peptides while minimizing unnecessary interference with TG2’s normal physiological roles.
With TransGlutex, we combine an allosteric TG2 concept with a delayed extended-release OROS formulation, helping the product narrative stay focused on local intestinal delivery.
The science
From gluten fragment to inflammatory cascade
Normally, gluten proteins are only partially digested in the intestine. TG2 can deamidate these gluten fragments, making them bind more strongly to HLA-DQ2 or HLA-DQ8 on antigen-presenting cells. This stronger binding can activate gluten-specific CD4+ T cells, stimulate B-cell antibody responses, and contribute to intestinal damage.
TG2 deamidation
TG2 chemically modifies gliadin/gluten peptides, which can increase their binding to HLA molecules.
HLA-DQ2/DQ8 presentation
Antigen-presenting cells present the modified fragments to gluten-specific CD4+ T cells.
Inflammatory response
T-cell activation strengthens the autoimmune response and can contribute to intestinal injury.
TransGlutex concept
Why allosteric TG2 modulation?
ZED1227 supports TG2 as a therapeutic target, but active-site inhibition may raise selectivity and systemic off-target concerns because TG2 is expressed across the body and has physiological roles such as wound healing and tissue remodeling. TransGlutex therefore explores a different idea: allosteric stabilization through the GTP-binding pocket.
Design hypothesis
If TG2 is stabilized in its inactive GTP-bound-like conformation, gluten peptides may become less immunogenic, weakening T-cell activation and the downstream autoimmune response.
Supporting evidence
The concept is grounded in structural and ADME evidence
We use the PoseView binding figure and the SwissADME output as supporting evidence for the concept story. Switch between both views and click the hotspots for the key findings.
Formulation design
TransGlutex is presented as a delayed extended-release OROS osmotic pump with an enteric coat.
The schematic below is the reference look for the product. Next to it, you can explore an interactive cutaway that explains how each layer contributes to gut-restricted and controlled release.
Interactive product cutaway
Explore the TransGlutex OROS tablet
Click or tap the numbered hotspots to highlight each layer and read what it does.
Core tablet
Release compartments and processing support
The core uses the same excipients in the push, slow-release, and fast-release regions, while the concentrations differ between sections to control ejection speed.
- Fillers / osmotic support: Microcrystalline cellulose, Mannitol, Polyethylene oxide
- Dry binder: Hydroxypropyl cellulose
- Glidant: Colloidal silicon dioxide
- Lubricant: Magnesium stearate
- Antiadherent: Talc
Semipermeable membrane
Water in, drug solution out only through the laser-drilled hole
Cellulose acetate forms the defining semipermeable membrane of the OROS system. Water can enter, osmotic pressure builds, and TEC keeps the film flexible under pressure.
- Membrane polymer: Cellulose acetate
- Plasticiser: Triethyl citrate
Enteric coat
Protection in the stomach, release in the small intestine
Eudragit L30D-55 is used as a pH-dependent coat to prevent release in the stomach while dissolving at small-intestinal pH. TEC supports flexibility and titanium dioxide provides the white appearance.
- Enteric polymer: Eudragit L30D-55 (Methacrylic acid copolymer)
- Plasticiser: Triethyl citrate
- Colourant: Titanium dioxide
Patient information leaflet wording
The active pharmaceutical ingredient is TransGlutex, each tablet contains 100 mg of TransGlutex. The excipients and other additives in this medicine are; Microcrystalline cellulose (E460i), Mannitol (E421), Polyethylene oxide (E1521), Hydroxypropyl cellulose (E463), Colloidal silicon dioxide (E551), Magnesium stearate (E470b), Talc (E553b), Cellulose acetate, Triethyl citrate (E1505), Eudragit L30D-55, Titanium dioxide (E171).
Packaging copy
Excipients and other additives: Microcrystalline cellulose (E460i), Mannitol (E421), Polyethylene oxide (E1521), Hydroxypropyl cellulose (E463), Colloidal silicon dioxide (E551), Magnesium stearate (E470b), Talc (E553b), Cellulose acetate, Triethyl citrate (E1505), Eudragit L30D-55, Titanium dioxide (E171).
Not required in this formulation
- No disintegrant: the drug is released gradually, so disintegration of the full core is not the objective.
- No sorbent: the drug is not formulated as a liquid or oil on a dry carrier.
- No flavouring agent: the enteric coat covers the tablet and oral taste is not the focus.
Investor thesis
A differentiated mechanism plus a credible formulation story.
The fictional investment case for Glutopia combines a differentiated allosteric TG2 mechanism, a gut-restriction strategy, and a dosage-form narrative that supports local delivery and controlled release.
Target rationaleTG2 remains a biologically validated node in coeliac disease.
Formulation advantageThe enteric-coated OROS concept supports release where the biology matters most.
Optimization pathPoseView and SwissADME insights create a clear next-step storyline.